Pinostilbene Inhibits Full-Length and Splice Variant of Androgen Receptor in Prostate Cancer

Investigators confirmed that pinostilbene directly bound to androgen receptor and inhibited its activation and translocalization. Their results suggested that pinostilbene has the potential to treat enzalutamide-resistant CRPC.